韩国人群中稳定的华法林剂量的新型基因多态性:全基因组协会研究
Jung Sun Kim1, Sak Lee2, Jeong Yee1
1Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea.
Biomedicines
|August 26, 2023
概括
这项研究确定了新型遗传变异NKX2-6,FRAS1和FAM201A,与韩国人的华法林剂量变化有关. 这些发现可能有助于为心脏门置换患者个性化华法林治疗.
科学领域:
- 药物基因组学 药物基因组学
- 心血管医学 心血管医学
- 遗传学 遗传学 是一个
背景情况:
- 华法林的剂量存在挑战,因为治疗窗口狭窄,个人间的差异很大.
- 现有的基因型导向的华法林剂量研究主要集中在欧洲人群上,限制了对其他种族的适用性.
研究的目的:
- 为了确定影响稳定的华法林剂量要求的新型遗传变异,在接受心脏门置换的韩国人群中.
- 通过全基因组关联研究 (GWAS) 方法,研究遗传和非遗传因素对华法林剂量可变性的综合影响.
主要方法:
- 一项回顾性队列研究,涉及214名韩国心脏置换患者.
- 全基因组关联研究 (GWAS) 具有宽松值 (5 × 10−7) 以确定与华法林维持剂量相关的遗传变异.
- 多变量回归分析,以确定遗传和非遗传因素对剂量变化的贡献.
主要成果:
- 最重要的遗传信号是在VKORC1基因附近的染色体16上检测到的.
- 在单变量分析中,三种新型变异 (NKX2-6 rs310279,FRAS1 rs4386623和FAM201A rs1890109) 与稳定的华法林剂量有关.
- 结合遗传和非遗传因素的多变量模型解释了58.5%的华法林剂量变化,其中VKORC1 rs9934438和FRAS1 rs4386623的贡献很大.
结论:
- 新型遗传变异 (NKX2-6,FRAS1,FAM201A) 与韩国人口中稳定的华法林剂量有关.
- 这些发现凸显了华法林药物基因组学中种族特异性遗传因素的潜力.
- 需要进一步的研究来验证这些变体,并为韩国患者开发个性化的华法林剂量策略.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Single Nucleotide Polymorphisms-SNPs
15.3K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
751
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
751
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
195
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
195
Comparing Copy Number Variations and SNPs
17.7K
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
17.7K
Factors Affecting Protein-Drug Binding: Patient-Related Factors
82
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
82


